BACKGROUND: Interleukin (IL)-6 -/- mice develop spontaneous mature onset obesity, while the influence of the pharmacological blockade of IL-6 on body weight in humans has not been previously reported. The aim of the present study was to observe weight change in patients treated with tocilizumab (TCZ). METHODS: Twenty-one consecutive patients who started new treatment with TCZ were enrolled in the study. Sixteen consecutive patients who started treatment with infliximab (IFX) formed the control group. Height and weight of all patients were registered and Body Mass Index (BMI) calculated before the first treatment and at week 16. The Mann-Whitney or paired Wilcoxon test were used for comparisons between or within groups, respectively. RESULTS: The study demonstrated that treatment with TCZ was accompanied with significant weight gain and BMI increase (p=0.04), while IFX treatment did not result in any significant weight change during the 16-week period. CONCLUSIONS: Weight gain can be seen in some patients during the pharmacological blockade of IL-6. The phenomenon and metabolic pathways involved should be further investigated.
BACKGROUND:Interleukin (IL)-6 -/- mice develop spontaneous mature onset obesity, while the influence of the pharmacological blockade of IL-6 on body weight in humans has not been previously reported. The aim of the present study was to observe weight change in patients treated with tocilizumab (TCZ). METHODS: Twenty-one consecutive patients who started new treatment with TCZ were enrolled in the study. Sixteen consecutive patients who started treatment with infliximab (IFX) formed the control group. Height and weight of all patients were registered and Body Mass Index (BMI) calculated before the first treatment and at week 16. The Mann-Whitney or paired Wilcoxon test were used for comparisons between or within groups, respectively. RESULTS: The study demonstrated that treatment with TCZ was accompanied with significant weight gain and BMI increase (p=0.04), while IFX treatment did not result in any significant weight change during the 16-week period. CONCLUSIONS:Weight gain can be seen in some patients during the pharmacological blockade of IL-6. The phenomenon and metabolic pathways involved should be further investigated.
Authors: Diana S Novikova; Helen V Udachkina; Eugenia I Markelova; Irina G Kirillova; Anna S Misiyuk; Natalia V Demidova; Tatiana V Popkova Journal: Rheumatol Int Date: 2019-05-03 Impact factor: 2.631
Authors: Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg Journal: Behav Brain Res Date: 2021-01-14 Impact factor: 3.332
Authors: Anne Tournadre; Bruno Pereira; Fréderic Dutheil; Charlotte Giraud; Daniel Courteix; Vincent Sapin; Thomas Frayssac; Sylvain Mathieu; Sandrine Malochet-Guinamand; Martin Soubrier Journal: J Cachexia Sarcopenia Muscle Date: 2017-03-18 Impact factor: 12.910
Authors: Elinoar Hoffman; Michal A Rahat; Joy Feld; Muna Elias; Itzhak Rosner; Lisa Kaly; Idit Lavie; Tal Gazitt; Devy Zisman Journal: Int J Mol Sci Date: 2019-09-18 Impact factor: 5.923